Document is current
Any future updates will be listed below
-
Authors
Boyer, Laurent http://orcid.org/0000-0003-1229-6622
Fond, Guillaume http://orcid.org/0000-0003-3249-2030
Pauly, Vanessa
Orléans, Veronica
Auquier, Pascal
Solmi, Marco http://orcid.org/0000-0003-4877-7233
Correll, Christoph U.
Yon, Dong Keon http://orcid.org/0000-0003-1628-9948
Llorca, Pierre-Michel http://orcid.org/0000-0001-7438-8990
Baumstarck-Barrau, Karine
Duclos, Antoine
- License Information
-
More Information
Article History
Received: 23 June 2022
Revised: 6 September 2022
Accepted: 14 September 2022
First Online: 7 October 2022
Competing interests
: LB has received honoraria/has been a consultant for Lundbeck. CUC has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma. P-ML has been a consultant and/or advisor to or has received honoraria from from Eli-Lilly, Janssen, Lundbeck, Otsuka and Teva, GF has received honoraria/has been a consultant for Lundbeck and Eisai. MS has received honoraria/has been a consultant for Angelini, Lundbeck, Otsuka. The other authors declare no competing interests.
